What development phase is Flunipam in?

Flunipam is FDA-approved (marketed).

What is the generic name of Flunipam?

FLUNITRAZEPAM is the generic (nonproprietary) name of Flunipam.

Last reviewed 2026-04-20 · How we verify

Flunipam (FLUNITRAZEPAM)

FDA-approved withdrawn Small molecule Quality 19/100

At a glance

Generic name	FLUNITRAZEPAM
Drug class	flunitrazepam
Target	Gamma-aminobutyric acid receptor subunit alpha-1, Gamma-aminobutyric acid receptor subunit alpha-2, Gamma-aminobutyric acid receptor subunit alpha-3
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly
Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Flunipam CI brief — competitive landscape report
Flunipam updates RSS · CI watch RSS